BMRA - Utang jangka dawa perusahaan Biomerica, Inc

Biomerica, Inc. (BMRA) develops diagnostics for gastroenterology, although regulatory costs create an operating loss and render cash flow unstable. Biomerica, Inc. (BMRA) generates revenue from rapid tests for pharmacies and clinics to detect food intolerances. This price chart on GURU.Markets, which clearly demonstrates changes, shows long-term debt at 0.00. High plant utilization and the automation of reagent filling support production capacity.

Biomerica, Inc. (BMRA) developments in the field of home GI diagnostics require significant investment, which is reflected in the company's level of long-term debt capital. This metric aggregates all credit obligations with a maturity of more than one year. The calculation is based on a real-time assessment of the balance sheet liability structure. It is critical for investors to monitor this volume to evaluate financial stability during the scaling of innovations, as a high debt load may reduce the asset's market value.